EIKN

Eikon Therapeutics, Inc.

Price Chart

Latest Quote

$9.61

-0.12 (-1.23%)

Current Price

Previous Close	$9.73
Open	$9.80
Day High	$10.20
Day Low	$9.32
Volume	320,267

Fetched: 2026-06-22T03:19:37

Stock Information

Shares Outstanding	54.14M
Total Debt	$254.83M
Cash Equivalents	$512.18M
Net Income	$-342.06M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$520.27M
EPS (TTM)	$-6.32
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$262.92M
Income	$-342.06M
Book/sh	$10.17
Cash/sh	$9.46
Employees	384

Financial Ratios

Quick Ratio	11.37
Current Ratio	11.75
Debt/Eq	46.28

Returns & Margins

Ownership

Insider Ownership	17.39%
Institutional Ownership	64.24%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.55
P/B	0.94

Analyst Data

Recommendation	none
Target Price	$24.80

Technical Indicators

SMA20	$9.66
SMA50	$10.19
RSI	38.24
ATR	0.8679

Shares Float	29.84M
Short Float	9.98%
Short Ratio	11.39
Rel Volume	1.16

Performance History

Week	+12.79%
Month	-9.68%
Quarter	-12.48%
YTD	-35.93%
10 Years	-35.93%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$9.61	320,300
2026-06-17	$9.73	265,700
2026-06-16	$9.07	190,000
2026-06-15	$9.33	316,000
2026-06-12	$8.75	228,900
2026-06-11	$8.52	248,200
2026-06-10	$8.36	155,100
2026-06-09	$8.77	205,000
2026-06-08	$8.98	189,000
2026-06-05	$8.96	229,300
2026-06-04	$9.78	283,200
2026-06-03	$9.43	353,900
2026-06-02	$9.60	219,600
2026-06-01	$10.79	213,000
2026-05-29	$10.84	200,600
2026-05-28	$10.30	696,300
2026-05-27	$10.37	374,800
2026-05-26	$9.90	402,400
2026-05-22	$10.91	223,700
2026-05-21	$11.16	185,200
2026-05-20	$10.66	236,600
2026-05-19	$10.64	428,100

About Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

📰 Latest News

Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls

The Fly • 2026-02-26T14:42:06Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Revenue
Total Revenue	$0	$0	$0
Operating Revenue	$0	$0	$0
Expenses
Interest Expense	$837,000	$31,000	$39,000
Total Expenses	$338,945,000	$260,343,000	$265,737,000
Other Income Expense	$-32,000	$-3,000	$42,000
Other Non Operating Income Expenses	$-32,000	$-3,000	$42,000
Net Non Operating Interest Income Expense	$14,729,000	$16,532,000	$23,698,000
Interest Expense Non Operating	$837,000	$31,000	$39,000
Operating Expense	$338,945,000	$260,343,000	$265,737,000
General And Administrative Expense	$88,627,000	$55,807,000	$58,476,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-324,248,000	$-243,814,000	$-241,997,000
Net Interest Income	$14,729,000	$16,532,000	$23,698,000
Interest Income	$15,566,000	$16,563,000	$23,737,000
Normalized Income	$-324,248,000	$-243,814,000	$-241,997,000
Net Income From Continuing And Discontinued Operation	$-324,248,000	$-243,814,000	$-241,997,000
Total Operating Income As Reported	$-338,945,000	$-260,343,000	$-265,737,000
Net Income Common Stockholders	$-333,644,000	$-243,814,000	$-241,997,000
Net Income	$-324,248,000	$-243,814,000	$-241,997,000
Net Income Including Noncontrolling Interests	$-324,248,000	$-243,814,000	$-241,997,000
Net Income Continuous Operations	$-324,248,000	$-243,814,000	$-241,997,000
Pretax Income	$-324,248,000	$-243,814,000	$-241,997,000
Interest Income Non Operating	$15,566,000	$16,563,000	$23,737,000
Operating Income	$-338,945,000	$-260,343,000	$-265,737,000
Per Share
Diluted EPS	$-6.18	$-7.45	$-7.40
Basic EPS	$-6.18	$-7.45	$-7.40
Other
Tax Effect Of Unusual Items	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-299,235,000	$-218,391,000	$-224,210,000
Reconciled Depreciation	$24,176,000	$25,392,000	$17,748,000
EBITDA (Bullshit earnings)	$-299,235,000	$-218,391,000	$-224,210,000
EBIT	$-323,411,000	$-243,783,000	$-241,958,000
Diluted Average Shares	$53,984,337	$32,707,651	$32,707,651
Basic Average Shares	$53,984,337	$32,707,651	$32,707,651
Diluted NI Availto Com Stockholders	$-333,644,000	$-243,814,000	$-241,997,000
Otherunder Preferred Stock Dividend	$9,396,000	$0	-
Research And Development	$250,318,000	$204,536,000	$207,261,000
Selling General And Administration	$88,627,000	$55,807,000	$58,476,000
Other Gand A	$88,627,000	$55,807,000	$58,476,000

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Assets
Net Tangible Assets	$-879,034,000	$-571,930,000	$-341,373,000
Total Assets	$594,734,000	$491,240,000	$525,705,000
Total Non Current Assets	$245,817,000	$263,351,000	$89,279,000
Other Non Current Assets	$8,354,000	$4,219,000	$2,399,000
Non Current Deferred Assets	$3,600,000	-	-
Current Assets	$348,917,000	$227,889,000	$436,425,000
Other Current Assets	$12,542,000	$7,378,000	$6,012,000
Restricted Cash	$400,000	$400,000	$0
Cash Cash Equivalents And Short Term Investments	$335,975,000	$220,111,000	$430,413,000
Cash And Cash Equivalents	$104,901,000	$129,179,000	$112,784,000
Cash Equivalents	$84,960,000	$15,813,000	$104,265,000
Cash Financial	$19,941,000	$113,366,000	$8,519,000
Debt
Total Debt	$257,319,000	$202,459,000	$31,735,000
Long Term Debt And Capital Lease Obligation	$247,291,000	$193,152,000	$26,687,000
Current Debt And Capital Lease Obligation	$10,028,000	$9,307,000	$5,048,000
Liabilities
Total Liabilities Net Minority Interest	$1,473,768,000	$1,063,170,000	$867,078,000
Total Non Current Liabilities Net Minority Interest	$1,418,761,000	$1,006,721,000	$835,638,000
Other Non Current Liabilities	$10,000,000	$5,348,000	$730,000
Current Liabilities	$55,007,000	$56,449,000	$31,440,000
Other Current Liabilities	$35,000	$301,000	$591,000
Payables And Accrued Expenses	$44,944,000	$46,841,000	$25,801,000
Payables	$681,000	$17,578,000	$2,187,000
Accounts Payable	$681,000	$17,578,000	$2,187,000
Equity
Common Stock Equity	$-879,034,000	$-571,930,000	$-341,373,000
Total Equity Gross Minority Interest	$-879,034,000	$-571,930,000	$-341,373,000
Stockholders Equity	$-879,034,000	$-571,930,000	$-341,373,000
Retained Earnings	$-920,509,000	$-604,941,000	$-361,127,000
Preferred Securities Outside Stock Equity	$1,161,470,000	$808,221,000	$808,221,000
Other
Ordinary Shares Number	$53,984,337	$53,984,337	$53,984,337
Share Issued	$53,984,337	$53,984,337	$53,984,337
Tangible Book Value	$-879,034,000	$-571,930,000	$-341,373,000
Invested Capital	$-879,034,000	$-571,930,000	$-341,373,000
Working Capital	$293,910,000	$171,440,000	$404,985,000
Capital Lease Obligations	$257,319,000	$202,459,000	$31,735,000
Total Capitalization	$-879,034,000	$-571,930,000	$-341,373,000
Additional Paid In Capital	$41,475,000	$33,011,000	$19,754,000
Capital Stock	$0	$0	$0
Common Stock	$0	$0	$0
Long Term Capital Lease Obligation	$247,291,000	$193,152,000	$26,687,000
Current Capital Lease Obligation	$10,028,000	$9,307,000	$5,048,000
Current Accrued Expenses	$44,263,000	$29,263,000	$23,614,000
Net PPE	$233,863,000	$259,132,000	$86,880,000
Accumulated Depreciation	$-42,914,000	$-33,902,000	$-18,895,000
Gross PPE	$276,777,000	$293,034,000	$105,775,000
Leases	$120,588,000	$18,613,000	$18,337,000
Construction In Progress	$624,000	$96,858,000	$5,416,000
Other Properties	$131,717,000	$158,281,000	$67,081,000
Machinery Furniture Equipment	$23,848,000	$19,282,000	$14,941,000
Properties	$0	$0	$0
Other Short Term Investments	$231,074,000	$90,932,000	$317,629,000

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31
Free Cash Flow
Free Cash Flow	$-235,257,000	$-219,602,000	$-219,361,000
Operating Activities
Operating Cash Flow	$-188,516,000	$-134,799,000	$-190,848,000
Cash Flow From Continuing Operating Activities	$-188,516,000	$-134,799,000	$-190,848,000
Investing Activities
Capital Expenditure	$-46,741,000	$-84,803,000	$-28,513,000
Investing Cash Flow	$-181,343,000	$151,350,000	$136,950,000
Cash Flow From Continuing Investing Activities	$-181,343,000	$151,350,000	$136,950,000
Financing Activities
Issuance Of Capital Stock	$352,053,000	$244,000	$105,812,000
Financing Cash Flow	$352,053,000	$244,000	$105,812,000
Cash Flow From Continuing Financing Activities	$352,053,000	$244,000	$105,812,000
Net Preferred Stock Issuance	$350,153,000	$0	$105,410,000
Preferred Stock Issuance	$350,153,000	$0	$105,410,000
Net Common Stock Issuance	$1,900,000	$244,000	$402,000
Common Stock Issuance	$1,900,000	$244,000	$402,000
Other
Interest Paid Supplemental Data	$889,000	$31,000	$39,000
End Cash Position	$113,072,000	$130,878,000	$114,083,000
Beginning Cash Position	$130,878,000	$114,083,000	$62,169,000
Changes In Cash	$-17,806,000	$16,795,000	$51,914,000
Net Investment Purchase And Sale	$-134,602,000	$236,153,000	$165,463,000
Sale Of Investment	$309,500,000	$596,500,000	$970,200,000
Purchase Of Investment	$-444,102,000	$-360,347,000	$-804,737,000
Net PPE Purchase And Sale	$-46,741,000	$-84,803,000	$-28,513,000
Purchase Of PPE	$-46,741,000	$-84,803,000	$-28,513,000
Change In Working Capital	$77,835,000	$80,650,000	$9,976,000
Change In Other Current Liabilities	$71,459,000	$75,721,000	$-6,792,000
Change In Other Current Assets	$-1,263,000	$-1,820,000	$1,268,000
Change In Payables And Accrued Expense	$12,803,000	$8,115,000	$17,330,000
Change In Accrued Expense	$16,616,000	$5,164,000	$17,091,000
Change In Payable	$-3,813,000	$2,951,000	$239,000
Change In Account Payable	$-3,813,000	$2,951,000	$239,000
Change In Prepaid Assets	$-5,164,000	$-1,366,000	$-1,830,000
Other Non Cash Items	$-5,541,000	$-9,456,000	$13,887,000
Stock Based Compensation	$18,036,000	$12,429,000	$9,538,000
Asset Impairment Charge	$21,226,000	$0	-
Depreciation Amortization Depletion	$24,176,000	$25,392,000	$17,748,000
Depreciation And Amortization	$24,176,000	$25,392,000	$17,748,000
Depreciation	$24,176,000	$25,392,000	$17,748,000
Net Income From Continuing Operations	$-324,248,000	$-243,814,000	$-241,997,000

Fetched: 2026-06-17